CloudCath

Focus: CloudCath develops a remote catheter monitoring platform focused on nephrology applications, specifically peritoneal dialysis and end-stage renal disease management. Founded in 2022 and headquartered in San Francisco, the company is early-stage with limited public financial disclosure.

Nephrology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About CloudCath

AI assessmentNot Hiring

No open roles listed right now. Follow CloudCath to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

CloudCath System

End Stage Renal Disease

N/A

Clinical Trials (1)

NCT05285436A Prospective Clinical Study to Assess the Clinical Utility of Turbidity in Patients Using In-Home Peritoneal Dialysis

N/A

Help build intelligence for CloudCath

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to shape a medical device startup from inception in a high-unmet-need area (nephrology/dialysis monitoring).
San Francisco location provides access to venture capital ecosystem and technology talent.
Early-stage positioning offers potential for significant equity upside if clinical validation succeeds.

Watch Out For

Company founded only in 2022 with no disclosed revenue, funding details, or employee count—minimal operational track record.
No active job postings (0 open roles), suggesting limited near-term hiring or possible contraction.
Pipeline programs are early-phase (non-traditional phase classification) with only 4 trials across multiple indications; clinical pathway unclear.

Generated by Claude from CloudCath's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

CloudCath Monitoring System

Peritoneal Dialysis-associated Peritonitis

N/A

Clinical Trials (1)

NCT04515498A Prospective Clinical Study of the CloudCath System During In-home Peritoneal Dialysis

N/A

Spectral characteristics assessment

Urinary Tract Infections

N/A

Clinical Trials (1)

NCT04950582In Vitro Analysis of Human Urine With the CloudCath Device

N/A

Effluent dialysate

Peritoneal Dialysis-associated Peritonitis

N/A

Clinical Trials (1)

NCT05300191In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2022

Portfolio: 4 clinical trials

Top TAs: Nephrology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Nephrology

3 pipeline

Marketed

Pipeline